- Cowden disease
- Cowden's disease
Your QuestionMy physician recently mentioned that I may be at risk for Cowden syndrome. What can you tell me about this condition?
We have identified the following information that we hope you find helpful. If you still have questions, please contact us.
Questions on this page
- What is Cowden syndrome?
- What symptoms are associated with Cowden sydnrome?
- What causes Cowden syndrome?
- Is genetic testing available for Cowden syndrome?
- How is Cowden syndrome diagnosed?
- How is Cowden syndrome inherited?
- How can I find a genetics professional in my area?
- How might Cowden syndrome be treated?
- Where can I obtain more information on Cowden syndrome?
People with Cowden syndrome also have an increased risk of developing several types of cancer, including cancers of the breast, thyroid, and the lining of the uterus (the endometrium). Noncancerous breast and thyroid diseases are also common. Other signs and symptoms of Cowden syndrome can include an enlarged head (macrocephaly); a rare, noncancerous brain tumor called Lhermitte-Duclos disease; and mental retardation. 
Most cases of Cowden syndrome and a small percentage of cases of Cowden-like syndrome result from mutations in the PTEN gene. PTEN is a tumor suppressor gene, which means that it normally prevents cells from growing and dividing too rapidly or in an uncontrolled way. Mutations in the PTEN gene have been identified in about 85 percent of people with Cowden syndrome. These mutations, which affect all of the body's cells, prevent the PTEN protein from effectively regulating cell survival and division. Uncontrolled cell division can lead to the formation of hamartomas and cancerous tumors.
Other cases of Cowden syndrome and Cowden-like syndrome result from changes involving the KLLN gene. This gene provides instructions for making a protein called killin. Like the protein produced from the PTEN gene, killin probably acts as a tumor suppressor. The genetic change that causes Cowden syndrome and Cowden-like syndrome is known as promoter hypermethylation. The promoter is a region of DNA near the gene that controls gene activity (expression). Hypermethylation occurs when too many small molecules called methyl groups are attached to the promoter region. The extra methyl groups reduce the expression of the KLLN gene, which means that less killin is produced. A reduced amount of killin may allow abnormal cells to survive and proliferate inappropriately, which can lead to the formation of tumors.
A small percentage of people with Cowden syndrome or Cowden-like syndrome have variations in the SDHB or SDHD gene. These genes provide instructions for making parts of an enzyme called succinate dehydrogenase (SDH), which is important for energy production in the cell. This enzyme also plays a role in signaling pathways that regulate cell survival and proliferation. Variations in the SDHB or SDHD gene alter the function of the SDH enzyme. Studies suggest that the defective enzyme may allow cells to grow and divide unchecked, leading to the formation of hamartomas and cancerous tumors. However, researchers are uncertain whether the identified SDHB and SDHD gene variants are directly associated with Cowden syndrome and Cowden-like syndrome. Some of the variants described above have also been identified in people without the features of these conditions.
When Cowden syndrome and Cowden-like syndrome are not related to changes in the PTEN, SDHB, SDHD, or KLLN genes, the cause of the conditions is unknown. 
Please note: Most of the laboratories listed through GeneTests do not accept direct contact from patients and their families; therefore, if you are interested in learning more, you will need to work with a health care provider or a genetics professional.
- Adult Lhermitte-Duclos disease (LDD), defined as the presence of a cerebellar dysplastic gangliocytoma
- Mucocutaneous lesions:
- Trichilemmomas (facial)
- Acral keratoses (thickened area of skin that may be red, yellow, or brown)
- Papillomatous lesions
- Mucosal lesions
- Breast cancer
- Thyroid cancer (non-medullary), especially follicular thyroid epithelial cancer
- Macrocephaly (head circumference 97th percentile)
- Endometrial carcinoma
- Other thyroid lesions (e.g., adenoma, multinodular goiter)
- Mental retardation (IQ 75)
- Hamartomatous intestinal polyps
- Fibrocystic disease of the breast
- Genitourinary tumors (especially renal cell carcinoma)
- Genitourinary malformation
- Uterine fibroids
A clinical diagnosis of Cowden syndrome is made if an individual meets any one of the following combinations:
- Pathognomonic mucocutaneous lesions alone if there are:
- Six or more facial papules, of which three or more must be trichilemmoma, or
- Cutaneous facial papules and oral mucosal papillomatosis, or
- Oral mucosal papillomatosis and acral keratoses, or
- Six or more palmo-plantar keratoses
- Two or more major criteria
- One major and at least three minor criteria
- At least four minor criteria
The following online resources can help you find a genetics professional in your community:
- The National Society of Genetic Counselors provides a searchable directory of US and international genetic counseling services.
- The American College of Medical Genetics has a searchable database of US genetics clinics.
- The University of Kansas Medical Center provides a list of US and international genetic centers, clinics, and departments.
- The American Society of Human Genetics maintains a database of its members, which includes individuals who live outside of the United States. Visit the link to obtain a list of the geneticists in your country, some of whom may be researchers that do not provide medical care.
Because people with Cowden syndrome have an increased risk of developing certain breast, thyroid, and endometrial cancers, an important aspect of management is increased cancer surveillance. Specific surveillance for breast cancer in individuals with Cowden syndrome includes monthly self-examination beginning at age 18 years (for females and males), annual clinical breast examinations beginning at age 25 years, and annual mammography and breast MRI beginning at age 30-35 years; surveillance for thyroid cancer includes baseline thyroid ultrasound examination at age 18 years and annual thyroid ultrasound examinations; surveillance for endometrial cancer includes annual suction biopsies beginning at age 35-40 years for premenopausal women and annual transvaginal ultrasound examination for postmenopausal women.
You can find information about Cowden sydrome on the Genetics Home Reference Web site. The Genetics Home Reference: Your Guide to Understanding Genetic Conditions is a service of the U.S. National Library of Medicine. This resource provides information about genetic diseases and associated genes, a glossary of genetic terms, descriptions of genetic concepts and links to other genetic resources. To view this information online, visit the following link.
- Cowden syndrome. Genetics Home Reference (GHR). March 2006; http://ghr.nlm.nih.gov/condition=cowdensyndrome. Accessed 5/18/2011.
- Eng C. PTEN Hamartoma Tumor Syndrome (PHTS). GeneReviews. May 5, 2009; http://www.ncbi.nlm.nih.gov/books/NBK1488/. Accessed 5/18/2011.
- Eng C. PTEN Hamartoma Tumor Syndrome. National Organization for Rare Disorders (NORD). 2007; http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/1186/viewAbstract. Accessed 5/18/2011.